On May 14, 2025, Hangzhou Testsea Biotechnology Co., Ltd.(hereinafter referred to as ” Testsealabs”) and Zhejiang hailiangbio Co., Ltd. (hereinafter referred to as “hailiangbio”) officially entered into a strategic cooperation agreement. The collaboration aims to accelerate the market deployment of stem cell-derived exosome products and WT1 tumor prevention solutions in key regions such as Southeast Asia, Europe, and Australia.
The signing ceremony marks the beginning of a new chapter in bilateral cooperation. Zhou Bin, General Manager of Testsealabs, stated during the event: “This partnership will be guided by the regional synergy strategy of ‘ Testsealabs in the North, hailiangbio in the South China Sea,’ establishing a benchmark model for Chinese biotech enterprises expanding globally.” As a pivotal step in Testsealabs’s internationalization strategy, the company anticipates leveraging Southeast Asia as a launchpad and harnessing the synergistic strengths of both entities to swiftly introduce core products, including stem cell exosomes and WT1 tumor prevention solutions, to the global market.
Dr. Lei Wei, General Manager of hailiangbio, highlighted: ” Testsealabs’s technical prowess in detection is widely recognized.” This collaboration is expected to not only diversify our product portfolio but also deliver high-quality medical solutions to the Southeast Asian market. We are confident in the promising prospects of this partnership.
Pursuant to the agreement, the two parties will focus on the following strategic directions:
1. **Joint Expansion of Global Markets**: Leveraging Testsealabs’s advanced detection technologies and hailiangbio’s extensive global channel resources, the collaboration will concentrate on three primary markets—Southeast Asia, Europe, and Australia—to expedite the internationalization of stem cell-derived exosome products and WT1 tumor prevention solutions.
2. **Establishment of a Detection Technology Innovation Ecosystem**: On the core front of technological cooperation, both parties aim to “break through technological boundaries and jointly establish global standards,” fostering multi-dimensional and in-depth collaborations. Market synergy will be strengthened through diverse initiatives such as brand partnerships and cross-border academic exchanges.
3. **Demonstration of Strategic Value and Industry Leadership**: The technical standards and localized service models co-developed by the two parties provide a replicable “dual-strong cooperation” model for Chinese biotech enterprises venturing abroad, driving the industry toward the mid-to-high end of the global value chain.
This strategic alliance represents a critical measure for Testsealabs and hailiangbio to leverage complementary strengths and achieve mutual benefit. Moving forward, both parties will establish a regular communication mechanism, periodically evaluate the progress of their collaboration, and ensure the efficient execution of all plans.
Following the signing ceremony, representatives from both companies took a commemorative group photo to mark this milestone moment. We are confident that through joint efforts, this partnership will inject fresh momentum into the development of the biopharmaceutical industry and make significant contributions to the global health cause.
Post time: May-22-2025